Source:http://linkedlifedata.com/resource/pubmed/id/17220902
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
2007-2-9
|
| pubmed:abstractText |
In this study, we retrospectively evaluated the efficacy and safety of total body irradiation (TBI) and granulocyte colony-stimulating factor (G-CSF)-combined high-dose cytarabine as a conditioning regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in patients with advanced myelodysplastic syndrome (MDS). We evaluated 22 patients with advanced MDS, including refractory anemia with excess blasts (RAEB; n=10), RAEB in transformation (n=2), acute myelogenous leukemia transformed from MDS (n=6) and chronic myelomonocytic leukemia (n=4). The conditioning regimen consisted of 12 Gy of TBI and high-dose cytarabine (3 g/m(2)) every 12 h for 4 days, and the cytarabine was combined with continuous administration of G-CSF. The stem cell sources were bone marrow or peripheral blood stem cells from human leukocyte antigen (HLA)-identical siblings (n=12) and bone marrow from HLA serologically matched unrelated donors (n=10). Three patients experienced disease relapse, two of whom died of disease progression. Of 22 patients, 16 are currently alive and disease-free. The 5-year estimated overall survival, disease-free survival, relapse and non-relapse mortality rates are 76.7, 72.2, 16.6 and 14.1%, respectively. These results suggest that G-CSF-combined high-dose cytarabine could be a promising component of the conditioning regimen of allogeneic HSCT for advanced MDS, providing a low incidence of both relapse and treatment-related mortality.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
0268-3369
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
39
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
217-21
|
| pubmed:meshHeading |
pubmed-meshheading:17220902-Adolescent,
pubmed-meshheading:17220902-Adult,
pubmed-meshheading:17220902-Bone Marrow Transplantation,
pubmed-meshheading:17220902-Cytarabine,
pubmed-meshheading:17220902-Disease Progression,
pubmed-meshheading:17220902-Disease-Free Survival,
pubmed-meshheading:17220902-Female,
pubmed-meshheading:17220902-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:17220902-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:17220902-Humans,
pubmed-meshheading:17220902-Male,
pubmed-meshheading:17220902-Middle Aged,
pubmed-meshheading:17220902-Myeloablative Agonists,
pubmed-meshheading:17220902-Myelodysplastic Syndromes,
pubmed-meshheading:17220902-Retrospective Studies,
pubmed-meshheading:17220902-Transplantation, Homologous,
pubmed-meshheading:17220902-Transplantation Conditioning,
pubmed-meshheading:17220902-Whole-Body Irradiation
|
| pubmed:year |
2007
|
| pubmed:articleTitle |
Total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine as a conditioning regimen in allogeneic hematopoietic stem cell transplantation for advanced myelodysplastic syndrome: a single-institute experience.
|
| pubmed:affiliation |
Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan. tmori@sc.itc.keio.ac.jp
|
| pubmed:publicationType |
Journal Article
|